Choline forms and memory tests
Comparison of bitartrate, lysolecithin and citicoline in separate memory tests.
Key points
- In healthy adults aged 18–29, a single dose of choline bitartrate showed no advantage over placebo on the three memory tests studied. This acute comparison does not support expecting a confirmed improvement in these memory measures. [1] See the evidence 1 2 3
- In adults aged 50–85 with age-related memory complaints, citicoline showed no advantage on the primary test over 12 weeks, although a secondary episodic memory test improved. For people with similar age-related complaints there is a preliminary signal of a better result on a specific secondary paired-associates test. [2] See the evidence 1 2
- In adults aged 40–74, lysolecithin showed no advantage over placebo in general memory over eight weeks. Based on this comparison, a confirmed improvement in general memory should not be expected when choosing lysolecithin. [3] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Different forms and memory tests were studied in different groups and regimens.
Key points
Why these conclusions
Different forms and results
In healthy adults aged 18–29, a single 2.5 g dose of choline bitartrate in juice, containing about 1 g choline, showed no advantage in spatial or verbal working memory or declarative recall. [1]
In adults aged 40–74, lysolecithin containing 480 mg lysophosphatidylcholine per day showed no advantage in general memory over eight weeks. [3]
In adults aged 50–85 with age-related memory complaints, 500 mg citicoline per day showed no advantage on the primary spatial test over 12 weeks. Improvement in the secondary paired-associates test was greater than with placebo. [2]
Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC have different compositions and amounts of elemental choline; results for one form do not transfer to another. [4] [3] [2] [5]
A single dose of choline bitartrate showed no advantage in spatial working memory.
| Parameter | Data |
|---|---|
| Result | A single dose of choline bitartrate showed no advantage in spatial working memory. Bitartrate 70±18% versus 72±16%, p=0.630; no advantage found. |
| Participants | Healthy adults aged 18–29; 40 began experiment 3, 37 completed it |
| Form | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Dose | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Dose basis | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Comparator | Placebo |
| Duration | Single dose in each phase, one-week interval |
| Confidence | 2/4: Precision: small sample and no CI for the difference.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: few losses and limited description of analysis procedures. |
| Evidence base | 1 trial |
| Sources | [1] |
A single dose of choline bitartrate showed no advantage in declarative recall.
| Parameter | Data |
|---|---|
| Result | A single dose of choline bitartrate showed no advantage in declarative recall. Bitartrate 71±15% versus 72±11%, p=0.489; no advantage found. |
| Participants | Healthy adults aged 18–29; 40 began experiment 3, 37 completed it |
| Form | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Dose | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Dose basis | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Comparator | Placebo |
| Duration | Single dose in each phase, one-week interval |
| Confidence | 2/4: Precision: small sample and no CI for the difference.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: few losses and limited description of analysis procedures. |
| Evidence base | 1 trial |
| Sources | [1] |
A single dose of choline bitartrate showed no advantage in verbal working memory.
| Parameter | Data |
|---|---|
| Result | A single dose of choline bitartrate showed no advantage in verbal working memory. Bitartrate 35±20 versus 35±19, p=0.987; no advantage found. |
| Participants | Healthy adults aged 18–29; 40 began experiment 3, 37 completed it |
| Form | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Dose | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Dose basis | Choline bitartrate 2.5 g (about 1 g choline) in 400 mL orange juice, orally |
| Comparator | Placebo |
| Duration | Single dose in each phase, one-week interval |
| Confidence | 2/4: Precision: small sample and no CI for the difference.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: few losses and limited description of analysis procedures. |
| Evidence base | 1 trial |
| Sources | [1] |
Lysolecithin showed no advantage in general memory over eight weeks.
| Parameter | Data |
|---|---|
| Result | Lysolecithin showed no advantage in general memory over eight weeks. WMS-R general memory: 100.8→110.7 versus 108.5→115.2; no significant between-group difference. |
| Participants | 46 adults aged 40–74, 23 and 22 analyzed |
| Form | Lysolecithin orally, 480 mg lysophosphatidylcholine per day |
| Dose | Lysolecithin orally, 480 mg lysophosphatidylcholine per day |
| Dose basis | Lysolecithin orally, 480 mg lysophosphatidylcholine per day |
| Comparator | Placebo |
| Duration | 8 weeks |
| Confidence | 2/4: Precision: 45 analyzed and no CI for the effect.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: marked baseline memory imbalance makes changes difficult to assess. |
| Evidence base | 1 trial |
| Sources | [3] |
Citicoline showed no advantage on the primary spatial memory test over 12 weeks.
| Parameter | Data |
|---|---|
| Result | Citicoline showed no advantage on the primary spatial memory test over 12 weeks. Spatial Span: 4.65→4.90 versus 4.75→4.67; no between-group advantage on the primary outcome. |
| Participants | 100 adults aged 50–85 with age-related memory complaints, 99 completed |
| Form | Citicoline orally 500 mg/day |
| Dose | Citicoline orally 500 mg/day |
| Dose basis | Citicoline orally 500 mg/day |
| Comparator | Placebo |
| Duration | 12 weeks |
| Confidence | 2/4: Precision: one RCT; the extracted data do not report the CI for the contrast.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: the comparison directly addresses the stated research question.; Possible publication bias: no data for a separate downgrade.; Study methods: industry funding and incomplete quantitative reporting of the primary contrast. |
| Evidence base | 1 trial |
| Sources | [2] |
On a secondary episodic memory test the score improved by 0.15 versus 0.06 points with placebo.
| Parameter | Data |
|---|---|
| Result | On a secondary episodic memory test the score improved by 0.15 versus 0.06 points with placebo. Paired Associates change +0.15 versus +0.06; p=0.0025 after adjustment for multiple comparisons. |
| Participants | 100 adults aged 50–85 with age-related memory complaints, 99 completed |
| Form | Citicoline orally 500 mg/day |
| Dose | Citicoline orally 500 mg/day |
| Dose basis | Citicoline orally 500 mg/day |
| Comparator | Placebo |
| Duration | 12 weeks |
| Confidence | 1/4: Precision: one RCT without an exact CI for the contrast in the extraction.; Consistency: no comparable independent series for this outcome and comparison.; Applicability to the specified group: a laboratory test does not measure preservation of daily function.; Possible publication bias: no data for a separate downgrade.; Study methods: secondary outcome in a test battery. |
| Evidence base | 1 trial |
| Sources | [2] |
Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC have different compositions and amounts of elemental choline; results for one form do not transfer to another.
Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC have different compositions and amounts of elemental choline; results for one form do not transfer to another. [4] [3] [2] [5]
Sources
- No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults. https://doi.org/10.1371/journal.pone.0157714
- Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC8349115/
- Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC11782770/
- NIH ODS Choline Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
- Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. https://pmc.ncbi.nlm.nih.gov/articles/PMC5629791/
Methodology: Subpages evidence-led supplement pipeline v1